Overall, Administration, rated as ?Outstanding? in the 2010 Summary Statement, holds the responsibility for managing and coordinating all financial and operational functions related to the strategic vision of the OSUCCC and CCSG. With Dr. Caligiuri assuming responsibilities as the OSUCCC Director as well as the CEO of the James Cancer Hospital in 2008, Administration was re-organized in 2010 in a similar fashion in order to integrate the administrative leadership to better facilitate the clinical and translational research mission of the OSUCCC. Further, the key roles that Administration now plays have grown considerably and are fully integrated across the Medical Center and the University to ensure the OSUCCC and CCSG needs are represented, prioritized and facilitated in an effective manner. Also in the 2010 Summary Statement, the reviewers rated Senior Leadership ?Exceptional?. Dr. Caligiuri now enters his 12th year as the OSUCCC Director and his 7th year as CEO of The James Cancer Hospital overseeing the entire cancer program at The Ohio State University. As the Director of the OSUCCC, Dr. Caligiuri has direct reporting to the Provost of the University and as CEO of the James Cancer Hospital he has direct reporting to the President of the University. To operate most effectively, Dr. Caligiuri has established a leadership structure with three key leadership positions directly reporting to him, the Senior Executive Director for Administration, the Deputy Director and the Physician-in-Chief. This executive team along with the Associate Directors of Basic Science, Clinical Research, Population Science, Biospecimen Research and Shared Resources as well as the Directors of Research Operations, Clinical Research Administration and Information Technology make up the core OSUCCC Senior Leadership Team. Now as the OSUCCC enters its 39TH year, the Senior Leadership team with Administration is responsible for coordinating the strategic growth of the Center, including facilitation of outstanding basic research programs, inter- and intra-programmatic collaboration, guiding translational and clinical research efforts, education and community outreach and provision of appropriate Shared Resource facilities. The team is also responsible for developing and executing long-term vision and strategic planning for the OSUCCC, and working towards the NCI goal to reduce morbidity and mortality from cancer. The changes that have occurred during the last funding cycle have been dramatic in terms of growth. Nonetheless, the path and vision set by the Director are for continued expansion of scientific discovery and translational research remains, with emphasis on our core strengths in cancer genetics, experimental therapeutics and prevention. Throughout this current cycle, Senior Leadership and Administration have worked together successfully to coordinate efforts and achieve several key accomplishments in support of the mission of the OSUCCC and CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843856
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications